• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
Esperion Therapeutics, Inc. (ESPR) Stock Price, News & Analysis

Esperion Therapeutics, Inc. (ESPR) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.53

$0.06

(2.43%)

Day's range
$2.45
Day's range
$2.54
50-day range
$1.58
Day's range
$2.6
  • Country: US
  • ISIN: US29664W1053
52 wk range
$1.16
Day's range
$3.4


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -5.45
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (ESPR)
  • Company Esperion Therapeutics, Inc.
  • Price $2.53
  • Changes Percentage (2.43%)
  • Change $0.06
  • Day Low $2.45
  • Day High $2.54
  • Year High $3.40

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $16.00
  • High Stock Price Target $20.00
  • Low Stock Price Target $12.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.90
  • Trailing P/E Ratio -3.11
  • Forward P/E Ratio -3.11
  • P/E Growth -3.11
  • Net Income $-209,248,000

Income Statement

Quarterly

Annual

Latest News of ESPR

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Esperion Therapeutics, Inc. Frequently Asked Questions

  • What is the Esperion Therapeutics, Inc. stock price today?

    Today's price of Esperion Therapeutics, Inc. is $2.53 — it has increased by +2.43% in the past 24 hours. Watch Esperion Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Esperion Therapeutics, Inc. release reports?

    Yes, you can track Esperion Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Esperion Therapeutics, Inc. stock forecast?

    Watch the Esperion Therapeutics, Inc. chart and read a more detailed Esperion Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Esperion Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Esperion Therapeutics, Inc. stock ticker.

  • How to buy Esperion Therapeutics, Inc. stocks?

    Like other stocks, ESPR shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Esperion Therapeutics, Inc.'s EBITDA?

    Esperion Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Esperion Therapeutics, Inc.’s financial statements.

  • What is the Esperion Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -1.7986831021, which equates to approximately -179.87%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Esperion Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Esperion Therapeutics, Inc.'s financials relevant news, and technical analysis. Esperion Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Esperion Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Esperion Therapeutics, Inc.’s technical analysis.

  • A revenue figure for Esperion Therapeutics, Inc. for its last quarter?

    Esperion Therapeutics, Inc. published it's last quarterly revenues at $51.63 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.